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Abstract

ANALYSIS OF PLASMINOGEN BINDING TO TREPONEMA DENTICOLA, A KEY
PERIOPATHOGEN
By: Brittney Kae Tegels
B.S. Biochemistry, University of St. Thomas, 2010
A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University
Virginia Commonwealth University, 2013
Director: Richard T. Marconi, Ph.D.
Professor, Department of Microbiology & Immunology

Periodontitis is a chronic inflammatory disease that affects over 116 million adults
in the United States. A shift in the normal microflora occurs as periodontal disease
develops resulting in a larger number of Gram-negative anaerobes and spirochetes. An
increase in the oral spirochete, Treponema denticola, is highly correlated with
periodontal disease progression and severity. The ability of this periopathogen to thrive
in the subgingival crevice is dependent on complement evasion mechanisms. Earlier
analyses demonstrated that the primary mechanism of T. denticola serum resistance is
binding of the human complement regulatory protein, Factor H (FH), to the factor Hbinding protein (FhbB). FH serves as cofactor in the Factor-I mediated cleavage of C3b
and accelerates the decay of the C3 convertase complex, leading to downregulation of
C3b production. Several pathogens bind FH, and a number of these bacterial binding

proteins have been shown to bind plasminogen. Plasminogen is a plasma glycoprotein
that circulates as a zymogen. Its active form, plasmin, degrades components of the
extracellular matrix and cleaves complement proteins C3b and C5 inhibiting
complement pathway progression. Through molecular and biochemical analyses, this
study demonstrates that FhbB simultaneously binds plasminogen and FH to residues
located on its positively and negatively charged surfaces, respectively, and that the two
ligands do not compete for binding.

This study also shows that the surface-bound

plasminogen is available for proteolytic cleavage into the active serine protease
plasmin. The activated plasmin could break down components of the periodontal tissue
leading to increased nutrient availability and creation of a larger anaerobic environment
where

the

bacteria

can

flourish,

thereby

promoting

periodontal

disease.

Chapter 1: Introduction

Periodontal Disease
Periodontitis, the most common infection among middle-aged adults (12), is a
broad clinical term used to describe the inflammation and infection of the ligaments and
tissue that support the teeth (Figure 1-1). The common clinical outcome of periodontitis
is deepening of periodontal pockets and destruction of the tissue that supports the tooth
(periodontium), progressively leading to alveolar bone resorption and eventual tooth
loss. As periodontal disease progresses, the pocket depth increases significantly and
the physiochemical properties of the subgingival crevice are altered. The early stages
of periodontal inflammation (gingivitis) can be corrected through treatment and
improved oral hygiene. Although the progression of advanced periodontal disease can
be stopped, complete restoration of the damaged tissue is impossible (76).
According to recent findings from the Centers for Disease Control and Prevention
(CDC), roughly one out of every two American adults aged 30 and over has periodontal
disease. Of that population, 38% aged 30 years and older and 64% aged 65 years and
older have severe or moderate periodontitis.

The study also highlights the

underestimation of periodontal disease in the US population; previous studies estimated
periodontal disease in adults aged 65 years or older at only 26% (15). The public health
burden of periodontal disease extends well beyond North America; a recent report from
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Figure 1-1.

Physiological changes of periodontium associated with the

development of periodontal disease.

Healthy periodontal tissue (left) contains

connective tissue and alveolar bone, which support the tooth. The space between the
gingival epithelium and the tooth surface is filled with gingival crevicular fluid. In cases
of periodontal disease (right), a dental-plaque biofilm accumulates on the tooth surface
leading to destruction of connective tissue and alveolar bone, resulting in eventual tooth
loss.
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the World Health Organization (WHO) showed that severe periodontitis exists in 5-20%
of adult populations worldwide (75).
Some factors may increase the likelihood of an individual developing periodontal
disease. Some of these risk factors include poor oral hygiene, socio-economic status,
malnutrition, age, hormonal state, smoking, and alcohol consumption (25, 39, 42, 88).
Among adults, smoking is responsible for more than half of the cases of periodontitis
(95).

Severe periodontitis’ health consequences can reach beyond the oral cavity.

Patients with severe periodontitis have an increased risk for heart disease, diabetes,
adverse pregnancy outcomes, and rheumatoid arthritis (reviewed in 76). In patients
with diabetes mellitus, the prevalence of periodontal symptoms is greater and the
progression of periodontal disease is more aggressive (93, 94). The economic cost of
treating periodontal disease and/or maintaining dental/oral health is staggering. Dental
visits and oral health problems result in roughly 164 million lost work hours each year at
a cost of 100 billion dollars (61).
Periodontitis is often described as a “polymicrobial disruption of host
homeostasis” (12). Under healthy conditions, the oral cavity consists of hundreds of
bacterial species that exist in a symbiotic relationship with their host. A shift in the
normal microflora occurs as periodontal disease develops, resulting in a larger number
of Gram-negative anaerobes and spirochetes present in the plaque (74).

The

subgingival plaque is complex with over 500 species represented, 57 of which belong to
the genus Treponema (14, 72, 73). Of the oral treponemes, Treponema denticola is the
dominant spirochete species, and a clear correlation between T. denticola and the
occurrence and severity of periodontal disease has been demonstrated (13, 16, 17).

3

Treponema denticola, serum resistance, and complement
Treponema denticola is a Gram-negative, obligate anaerobic bacterium. In the
healthy subgingival crevice, T. denticola represents <1% of the total bacterial
population; however, in periodontal pockets this number can exceed 40% (14). The
plaque biofilm builds from the tooth outwards with the superficial layers in close
association with the gingival epithelium. T. denticola is located in the superficial layer
as a part of the red complex with Prophyromonas gingivalis and Tannerella forsythia,
and is subsequently exposed to soft tissue and gingival crevicular fluid (GCF) (89).
GCF is a serum and local tissue exudate that collects locally around each tooth surface.
GCF contains a variety of host and microorganism-derived substances, including
markers of inflammation. GCF recovered from periodontal disease patients is rich in
immune effectors including activated complement (12). T. denticola is resistant up to
40% serum (Marconi RT unpublished data). This level of serum resistance is sufficient
for survival in the levels of complement encountered in the GCF. Thus, the ability of T.
denticola to thrive in the subgingival crevice is dependent on evading complement
mediated destruction.
The complement system is the oldest branch of the immune system that
recognizes bacterial pathogens, marks them for destruction, and clears the infection
from the host (Figure 1-2). Specific complement proteins bind to the surface of bacteria
and activate the complement cascade resulting in formation of the membrane attack
complex (MAC), deposition of opsonins (C3b and iC3b) on the surface of pathogens,
production of anaphylatoxins (C3a and C5a), and stimulation of active immunity.
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Figure 1-2. Complement activation pathways and the negative regulatory role of
Factor H.

Complement activation is initiated by the classical, lectin, or alternative

pathway. All three activation cascades lead to production of opsonins (C3b, iC3b) and
anaphylatoxins (C3a, C5a), and the formation of the membrane attack complex (C5b-9).
Factor H inhibits alternative complement activation through cofactor activity in the
Factor-I mediated cleavage of C3b, by facilitating the disassembly of preformed C3
(C3bBb) and C5 (C3bBbC3b) convertase, and by blocking formation of new C3
convertase by competing with Factor B for binding to C3b.
5

However, complement activity must be regulated to prevent damage to host cells or
tissue.

Factor H (FH) is a highly abundant (400-800 mg ml-1 serum) complement

regulator that healthy cells bind to their surface to protect themselves from complement
mediated destruction. FH regulates the alternative complement pathway at the level of
C3b by: (1) serving as a cofactor for Factor I-mediated cleavage of C3b, (2) accelerating
decay of preformed C3 convertase, and (3) competing with Factor B for binding to C3b
to block formation of new C3 convertase (84, 85, 105).

Mechanisms of T. denticola complement evasion
The presence of subgingival plaque and subsequent biofilm formation offers
passive protection to T. denticola by providing a barrier against immune effector cells,
complement, and antibody.

T. denticola also employs active mechanisms of

complement evasion, one of which is production of dentilisin.

Dentilisin is a multi-

subunit chymotrypsin-like protease (CTLP) complex that has a wide range of cytopathic
effects on cells and tissue. These various effects facilitate penetration and translocation
of T. denticola through cell monolayers and extracellular matrix (ECM) models (9, 18,
97). Dentilisin is also a complement degrading protease that has been demonstrated to
cleave C3, C3b, and FH (60, 108). Cleavage of these key complement proteins likely
favors dysregulation of tissue homeostasis of the subgingival crevice.
T. denticola also actively evades complement mediated destruction by utilizing
the negative regulatory effects of FH. It accomplishes this through binding of FH to its
surface via the factor H-binding protein B (FhbB) (58). FhbB is the smallest bacterially
produced FH-binding protein identified to date with a molecular weight of 11.4 kDa. It is
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the only FH binding protein produced by T. denticola and it has no discernible sequence
homology with other bacterial FH binding proteins (58).

Phylogenetic sequence

analyses of fhbB from over 30 T. denticola isolates revealed the existence of three
distinct major FhbB phyletic types (Marconi RT unpublished data, Figure 1-3). The
structure of FhbB was recently solved and shown to consist of an ααβαβ fold with welldefined negatively (α1-α2) and positively (β1-α3-β2) charged surfaces (66). The FH
binding site was characterized to the negatively charged face of FhbB. Residues E45,
D58, and E62 located on the negatively charged face are required for FH binding as
alanine substitution mutagenesis abolished FH binding to the mutated residues (66).
FH consists of 20 imperfect repeat units referred to as complement control protein
(CCP) domains (23). FhbB was demonstrated to bind CCP7 of FH (66). CCP7 serves
as an interaction site for glycosaminoglycans presented on host cell surfaces and within
the extracellular matrix thereby preventing targeting of host tissues by complement (27).
Recent data suggests that the CCP7 binding sites for glycosaminoglycans and FhbB
partially overlap (66).
Serum resistance analyses of T. denticola mutant strains lacking fhbB
(35405ΔfhbB) and dentilisin (CCE) elucidated their contribution to evading complement
encountered in the gingival crevicular fluid.

When incubated with 25% serum, the

serum sensitivity of 35405ΔfhbB was markedly increased compared to the wild type
strain 35405 with cell survival at 15% and 85%, respectively (57). However, the serum
sensitivity of CCE was at wild-type serum resistance levels demonstrating that dentilisin
is not required for complement evasion. It was concluded that FhbB FH binding is the
primary mechanism of T. denticola serum resistance.
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Figure 1-3. Phylogenetic tree of mature FhbB from Treponema denticola isolates.
Mature FhbB sequences were aligned and the phylogenetic analyses were performed
using MEGA5. The phylogenetic tree is rooted with FhbA, a factor H-binding protein of
Borrelia hermsii. Phyletic types 1 and 2 are highly conserved while type 3 is more
divergent.
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A unique feature of dentilisin is its ability to cleave T. denticola surface-bound FH
(60). Cleavage of FH is somewhat of a paradox as binding of FH serves to protect T.
denticola against complement mediated attack. If dentilisin cleaves FH to depletion, the
expectation would be that T. denticola would be more susceptible to complement
mediated degradation.

It has been proposed that when T. denticola establishes

infection it is important for the periopathogen to have FH bound to the cell surface to
evade complement. However, once the plaque biofilm has formed, there would be a
colony of cells protecting the pathogen. At that point, it is thought that T. denticola uses
dentilisin to cleave FhbB-bound FH as well as the host’s population of FH.

This

cleavage event would deplete the local population of FH used by healthy cells and lead
to immune dysregulation as the host’s complement would begin to attack healthy cells.
The resultant tissue destruction would provide nutrients to the periopathogen and create
a larger periodontal pocket where the bacteria can thrive (61).

Plasminogen
Plasminogen (Plg) binding to bacterial cell surfaces is a common mechanism
pathogens use when interacting with hosts. Plasminogen is synthesized in the liver as
a 90 kDa polypeptide chain that circulates in plasma (200 µg mL-1) as the inactive
zymogen form of the enzyme plasmin (1, 79).

Several forms of plasminogen are

present in the plasma as a result of posttranslational processing (Figure 1-4). The
mature form of plasminogen is known as Glu-plasminogen (Glu-Plg) due to the
presence of the glutamic acid residue at the N-terminus. Glu-Plg consists of the
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Adapted from © Sanderson-Smith, M.L., et al. 2012. Bacterial
Plasminogen Receptors: Mediators of a Multifaceted Relationship.
Journal of Biomedicine and Biotechnology. Article ID 272148.

Figure 1-4. Structural domains of human plasmin(ogen) forms. The circulating
mature form of plasminogen is known as Glu-plasminogen (Glu-Plg) due to the
presence of the glutamic acid residue at the N-terminus. Glu-Plg consists of the Nterminal activation peptide (PAP) followed by a series of 5 repeating peptide regions
termed kringle domains (K1-K5), followed by the serine protease active site (SPD). The
activation loop (R561-V562) of Glu-Plg is cleaved by specific plasminogen activators
like urokinase forming Glu-plasmin (Glu-Pln). Glu-Pln can cleave the PAP from Glu-Plg
or Glu-Pln via the Lys77-Lys78 peptide bond forming Lys-plasminogen (Lys-Plg) or Lysplasmin (Lys-Pln), respectively. The resulting two-chain Glu- or Lys-plasmin molecule
consist of heavy chain A and light chain B, which remain covalently associated by
interchain disulfide bonds.
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N-terminal activation peptide (PAP) followed by a series of 5 repeating peptide regions
termed kringle domains (K1-K5). The function of the kringles is to mediate proteinprotein interactions, typically through binding of C-terminal and internal receptor lysine
residues to the lysine binding sites (LBS) within the kringle domains.

The kringle

domains display varying affinities for free lysine or lysine analogues (K1 > K4 > K5 >
K2) (54); K3 does not bind plasminogen (91). The C-terminal region of Glu-Plg contains
the serine protease active site (SPD) comprised of amino acid residues His603,
Asp646, and Ser741, which make up the catalytic triad of the active domain (79). This
domain can recruit adaptor molecules, or cofactors, such as bacterial plasminogen
activators (PAs) streptokinase and staphylokinase, which modify the substrate
presentation to the enzyme and modulate its specificity (71).
Glu-Plg can adopt two different conformations, T and R.
formation) is seen in full length human plasminogen.

The T state (tight

In this state, plasminogen is

poorly activated due to intramolecular forces between lysine residues and the LBS of
the kringle domains (46, 79, 98, 99). Competitive binding interactions with plasminogen
receptors at residues K77-K78 change the conformation of Glu-Plg to the R state
(relaxed formation), exposing the activation loop (Arg561-Val562) that can be cleaved
by specific PAs thus forming Glu-plasmin (Glu-Pln), the active serine protease (79, 80).
Once formed, Glu-Pln can cleave the activation peptide from Glu-Plg or Glu-Pln via the
Lys77-Lys78 peptide bond thus forming Lys-plasminogen or Lys-plasmin, respectively.
The Lys-plasminogen formation is more readily activated to Lys-plasmin by the PAs due
to its open conformation (35, 79, 102). The resulting two-chain Glu- or Lys-plasmin
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molecule consists of a heavy and light chain in the N and C-terminal region,
respectively, and is held together by interchain disulfide bonds.
Utilization of the host plasminogen activation system during infection is a
common mechanism various pathogens employ (10, 44, 56, 103). Bacteria interact with
the plasminogen system by expressing plasminogen receptors on their surface and
secreting PAs like streptokinase and staphylokinase to activate surface-bound Plg to
plasmin (77). The plasminogen receptors direct plasmin activity to locations where
proteolytic activity may be required. Plasmin can degrade fibrin clots through a process
called fibrinolysis as well as various ECM components.

This offers a potential

proteolytic system that could be utilized by pathogenic bacteria to enter and disseminate
into the host’s system (48, 49).
In addition to degradation of ECM components, plasminogen is involved in the
immune system at multiple levels. In the complement pathway, plasminogen functions
as a C3- and C5-binding protein, and activated plasmin degrades and inactivates the
two major complement proteins C3b and C5 (3). Degradation of C3b by plasmin blocks
C3b effector functions like cascade progression to C3 and C5 convertase. Without the
C3 and C5 convertase the C3b opsonin is not deposited on bacterial cell surfaces, the
anaphylatoxins C5a and C3a are not produced, and the MAC is not formed.
Plasminogen binding has also been shown to enhance the cofactor activity of FH in the
inactivation of C3b by the complement protease Factor I (FI) (3). Activated plasmin is
also capable of degrading immunoglobulin (Ig) molecules (11, 33, 41, 101).

Ig

molecules function as opsonins, and the Fc portions of Ig are recognized by specialized
Fc receptors expressed by phagocytic cells such as macrophages and neutrophils. The
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Fc portions can also bind to the classical complement C1q complex and initiate the
complement cascade.
Several pathogenic microbes bind plasminogen to their surface and utilize its
effector functions. Multiple plasminogen-binding proteins have been identified, and the
binding of plasminogen to these proteins is typically mediated by lysine residues. Some
examples include FhbA from B. hermsii (83), OspE, CspZ, and CspA from B.
burgdorferi (6, 32), and HcpA from B. recurrentis (31).

Interestingly, all of these

plasminogen-binding proteins bind the complement regulator FH and exploit its negative
regulatory function also (31, 34, 36, 37, 40, 62-64, 81, 83, 87).

Research objective
It is evident that plasminogen binding to bacterial cell surfaces is an important
dissemination and immune evasion mechanism. Multiple bacterial plasminogen-binding
proteins have been demonstrated to bind additional complement regulators such as FH
to evade complement-mediated destruction. As FhbB is the only FH-binding protein
produced by T. denticola and complement evasion is essential for the periopathogen’s
survival in the periodontal pocket, we sought to characterize plasminogen binding to
FhbB. Through biochemical methods such as plasminogen binding assays, inhibition
and competition assays, amino acid substitution, and activation and degradation
assays, our lab has demonstrated that FhbB binds plasminogen to its surface, and that
the surface bound plasminogen is available for proteolytic cleavage into the active
serine protease plasmin.
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Chapter 2: Materials and Methods

Bacterial cultures and growth conditions
T. denticola strains 35405, 33521, SP46, SP54, SP72, SP61, and CCE were
grown anaerobically in New Oral Spirochete (NOS) medium as described previously
(59). CCE is a derivative strain of T. denticola 35405 in which specific regions of the
operon that code for dentilisin were inactivated by allelic exchange and insertion of an
erythromycin cassette (22).

Protein expression and purification
All recombinant proteins in this study were expressed in LB Broth, Lennox
(Fisher BioReagents) supplemented with 100 mg/L ampicillin (Fisher BioReagents).
Cultures of the transformed NovaBlue (DE3) cells were grown to exponential phase at
37°C, and protein expression was induced with isopropyl β-D-1-thiogalactopyranoside
(IPTG) at a 10 mM concentration for 8 hours at 37°C.

Cells were pelleted by

centrifugation (5,000 x g, 15 min, 4°C), frozen, resuspended in lysis buffer (50 mM
NaH2PO4, 300 mM NaCl, 10 mM Imidazole [pH 8.0], lysozyme [1 mg/mL]), incubated on
ice (1 hour), sonicated, and centrifuged (10,000 x g, 30 min, 4°C). Soluble protein was
purified from the supernatant using Ni-NTA affinity chromatography with His-trap
columns (GE Healthcare) on an AKTA Purifier (GE Healthcare). The purified proteins
were dialyzed into phosphate-buffered saline (PBS) using Spectra/Por dialysis
14

membranes (Spectrum Laboratories). Protein concentrations were determined using a
BCA protein assay kit (Thermo Scientific), and visualized via sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) (BioRad) and stained with Coomassie
Brilliant Blue to assess purity. The recombinant FhbB mutants were generated as part
of a previous study and were purified as described above (66).

Plasminogen binding ELISAs
Microtiter plates (Corning Costar) were coated (in triplicate; 1 µg per well in 100
mM NaHCO3, pH 9.6, overnight at 4°C) with various recombinant FhbB proteins from
Treponema denticola strains 35405 (wild type), SP50, 35404, 33521, CF170, and SP46,
or with the various FhbB double amino acid mutants.

OspA, a known borrelial

plasminogen ligand (24), was used as a positive control and bovine serum albumin
(BSA) served as a negative control. Plates were washed with tris-buffered saline (TBS)
containing 0.2% Tween 20 (TBST) and blocked for 2 hours at room temperature with
TBST containing 5% BSA (TBSTB). After washing the wells three times with TBST,
plasminogen (1-4 µg/mL in TBSTB; Calbiochem) was added and incubated for 1 hour.
Thereafter, the wells were washed and incubated for 1 hour with goat anti-human
plasminogen (1:1,000 in TBSTB; Rockland Immunochemicals). Subsequently the wells
were washed, rabbit anti-goat IgG (1:20,000 in TBSTB; Calbiochem) was added for 1
hour, the wells washed a final time, and signal was detected using 2,2’-azino-bis(3ethylbenzothiazoline-6-sulphonic acid) (ABTS) at 405 nm.
For experiments examining the role of lysine residues in the plasminogen-FhbB
interaction, the lysine analogue ε-aminocaproic acid (ε-ACA) (1-40 µM; Sigma Aldrich)
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was added with plasminogen (10 µg/mL; Calbiochem) to recombinant FhbB-coated
wells. To determine if plasminogen and FH compete for binding to FhbB, increasing
molar ratios of plasminogen (see text for concentrations; Calbiochem) was added with
purified FH (5 µg/mL; Complement Tech) to recombinant FhbB-coated wells. Binding
was detected with goat anti-human FH (1:1,000 in TBSTB; Complement Tech) and goat
anti-human plasminogen (1:1,000 in TBSTB; Rockland Immunochemicals) with rabbit
anti-goat IgG serving as the secondary (1:20,000 in TBSTB; CalBiochem).

Three

independent replicates were performed for each plasminogen binding assay.

Cofactor assay
The ability of T. denticola-bound plasminogen to enhance the cofactor activity of
FH in the Factor I-mediated cleavage of C3b was assessed with a cleavage assay. T.
denticola CCE cells grown to mid-log phase were recovered by centrifugation (5,000 x
g, 15 min, 4°C), washed twice with PBS, and the cell density determined by measuring
the absorbance at 600 nm (OD600). T. denticola CCE is a dentilisin gene inactivation
mutant strain and was used in this assay because dentilisin cleaves C3b (60). Aliquots
(0.5 OD600) were suspended in PBS (100 µl) with plasminogen (1, 5, 10 µg/mL;
CalBiochem) and FH (5 µg/mL; Complement Tech), and incubated for 1 hour at 37°C.
The cells were centrifuged (5 min; 5,000 x g) to remove unbound plasminogen/FH, the
cell pellet was suspended in PBS (100 µl) with Factor I (1.5 µg/mL; Complement Tech)
and C3b (5 µg/mL; Complement Tech), and incubated for 2 hours at 37°C.

After

incubation, SDS-PAGE sample buffer was added (1:1 ratio), and the samples were
fractionated by SDS-PAGE (Bio-Rad) and transferred to a PVDF membrane
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(Immobilon; Millipore). Non-specific binding was blocked by incubating the membrane
with PBS containing 0.2% Tween 20 (PBST) and 5% nonfat dry milk (PBSTM) at room
temperature for 1 hour. After washing three times with PBST, C3b degradation was
detected with goat anti-human C3 (1:1000 in PBSTM; Complement Tech) with rabbit
anti-goat IgG serving as the secondary (1:20,000 in PBSTM; CalBiochem). Signal was
detected by chemiluminescence with the SuperSignal West Pico Western blotting
substrate (Thermo). The controls for this assay consisted of reactions containing CCE
cells with purified human C3b, FI, FH, and/or plasminogen. The purpose of this set of
controls was to demonstrate the specificity of C3b cleavage by FI and that cleavage is
dependent on the presence of FH.

Dentilisin activity and plasminogen degradation assay
The ability of dentilisin to degrade plasminogen was examined via a cell cleavage
assay. T. denticola cells grown to mid-log phase were recovered and quantified as
described above.

Aliquots (0.1 OD600) were suspended in PBS (50 µl) with

plasminogen (1 µg/mL; CalBiochem) and incubated for 2 hours at 37°C with rotation
(500 rpm). Samples were collected at 0 and 2 hours, SDS-PAGE sample buffer was
added (1:1 ratio), and the samples were assessed by SDS-PAGE and transferred to
PVDF. To determine if the various T. denticola strains degraded plasminogen, the
membrane was screened with goat anti-human plasminogen (1:1000 in PBSTM;
CalBiochem).

The procedure for immunoblot analysis was performed as described

above. The dentilisin activity of all strains was measured by monitoring hydrolysis of
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succinyl-L-alanyl-L-alanyl-L-prolyl-L-phenylalanine-p-nitroanilide

(SAAPFNA),

as

previously described (57, 96).

Plasminogen activation assay
T. denticola cells grown to mid-log phase were recovered and quantified as
described above.

Aliquots (0.25 OD600) were suspended in PBS (100 µl) with

plasminogen (50 µg/mL; CalBiochem) and urokinase (uPA) (630 µg/mL; Sigma), and
incubated for 2 hours at 37°C with rotation (500 rpm). Following incubation, the cells
were centrifuged (5 min; 5,000 x g) and washed with PBS three times, and the OD600
determined. Aliquots (0.25 OD600) were suspended in PBS (500 µl) and immobilized
(100 µl; in triplicate) in a microtiter plate (Corning Costar). The wells were incubated
with 100 µl of

D-Val-Leu-Lys

4-nitroanilide dihydrochloride (125 µg/mL; Sigma) and

plasmin activity was recorded at intervals of 1 hour at 37°C (405 nm; ELx808 Bio-Tek).
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Chapter 3: Results

FhbB binds plasminogen.
Some bacterially produced Factor H (FH) binding proteins are multi-functional
and bind other host-derived ligands including plasminogen (6, 31, 32, 43, 50, 78, 83).
To determine if FhbB binds plasminogen, an ELISA-based approach was used where
recombinant OspA, FhbB, and BSA were immobilized in a microtiter plate and overlaid
with increasing concentrations of plasminogen. Plasminogen bound to immobilized
FhbB in a concentration-dependent manner (Figure 3-1).

The known borrelial

plasminogen ligand OspA (24) was used as a positive control and BSA as a negative
control.

Lysine residues are involved in FhbB plasminogen binding.
The kringle domains of plasminogen have been demonstrated to interact with
lysine residues of bacterial receptors (6, 31, 32, 79, 100, 106). To analyze whether
lysine residues are relevant to the plasminogen-FhbB interaction, the lysine analogue εaminocaproic acid (ε-ACA) was utilized.

The synthetic lysine analogue inhibited

plasminogen binding to FhbB in a concentration-dependent manner, strongly
suggesting lysine residues of FhbB are involved in binding to the LBS of plasminogen
(Figure 3-2).
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Figure 3-1. Binding of plasminogen to factor H-binding protein B (FhbB). Binding
of plasminogen to immobilized FhbB, analyzed by enzyme-linked immunosorbent
assay. Results are representative of 3 independent experiments; error bars indicate
standard deviations. A405, absorbance measured at 405 nm.
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Figure 3-2. Inhibition of FhbB plasminogen binding by the lysine analogue εACA.

r-FhbB was immobilized and overlaid with combinations of plasminogen (10

μg/mL) and increasing μM concentrations of ε-ACA. r-FhbB incubated with buffer alone
served as a negative control. Plasminogen binding was detected by sequential addition
of goat anti-human plasminogen (1:1,000), HRP-conjugated rabbit anti-goat (1:20,000),
and 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid). Results are representative
of 3 independent experiments; error bars indicate standard deviations.
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Positively charged amino acid residues mediate the plasminogen-FhbB binding
interaction.
The FH binding site has previously been characterized to the negatively charged
face of FhbB (Figure 3-3A) (66).

The inhibition of plasminogen binding by ε-ACA

suggested that plasminogen may bind to lysine residues located on the positively
charged face of FhbB. To determine this, recombinant wild type FhbB and double
amino acid substitution mutants were tested for plasminogen binding. Substitution of
positively charged amino acids, including lysine residues, significantly reduced
plasminogen binding (47/50, 77/78, and 93/94; Figure 3-3B) while substitution of
negatively charged amino acids had no effect (58/62 and 62/66, Fig 3-3B). This result
demonstrated that plasminogen binds to multiple residues on the positively charged
surface of FhbB.

Plasminogen and FH bind to separable FhbB binding sites.
The FhbB structure is highly ordered consisting of a negatively charged face and
a positively charged face with FH binding characterized to the negatively charged face
(66). The inhibition of plasminogen binding by the lysine analogue ε-ACA, and the
decrease in plasminogen binding observed for the positively charged double-amino acid
mutants, suggested that plasminogen was binding to the positively charged face of
FhbB. To determine if FH and plasminogen compete for binding, recombinant FhbB
was immobilized in a microtiter plate and binding of FH was assessed with increasing
molar concentrations of human plasminogen. Increasing concentrations of plasminogen
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A.

B.

Figure 3-3. Mediation of plasminogen binding by positively charged amino acid
residues.

A, the electrostatic surface charge maps are presented.

Positive and

negative charges are depicted in blue and red, respectively. The amino acid residues
targeted for substitution are labeled on the appropriate face of FhbB. B, measurement
of plasminogen binding to recombinant wild type and double amino acid FhbB
substitution mutants by ELISA. Plasminogen binding was detected as described above
and is represented as % binding relative to 35405. Results are representative of 3
independent experiments; error bars indicate standard deviations. *P < 0.01 compared
to 35405 (Student t test).
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had no effect on FH binding suggesting the binding sites for the two ligands are on
opposite faces of FhbB with little or no overlap (Figure 3-4).

FhbB phyletic type has no effect on plasminogen binding.
Phylogenetic analyses of fhbB from a panel of T. denticola isolates identified
three distinct FhbB phyletic types. Sequence variation among these types localizes
primarily within the FH binding interface (Marconi RT unpublished data). To determine
if sequence differences influence plasminogen binding, recombinant FhbB proteins of
each phyletic type were immobilized in ELISA plates and coated with plasminogen.
Equivalent binding across types 1 and 2 was observed while binding to type 3 isolates
was varied (Figure 3-5).

Although plasminogen binding to 33521 and SP46 is

significantly lower than 35405, the effect is less drastic compared to FH binding across
phyletic types (Marconi RT unpublished data). This observation is consistent with the
conserved nature of the positively charged face of FhbB which appears to serve as the
plasminogen binding interface (Marconi RT unpublished data).

Plasminogen binding does not enhance the cofactor activity of FH.
Plasminogen has been shown to enhance Factor I-mediated C3b degradation in
the presence of the cofactor FH (3).

As plasminogen and FH bind to FhbB

simultaneously, the ability of plasminogen to influence cofactor activity was assessed.
Factor H, Factor I, and increasing concentrations of plasminogen were added to C3b
and T. denticola CCE cells. After incubation, the reaction mixture was separated by
SDS-PAGE and cleavage products were identified by Western blotting described above.
Intact C3b was detected by the presence of α’ and β-chains (Figure 3-6). Factor I in the
24

Figure 3-4.

Plasminogen-Factor H competitive binding analyses.

r-FhbB was

immobilized and binding of plasminogen and FH were analyzed by ELISA.

Upon

addition of plasminogen (molar ratios are shown), binding was visualized by sequential
addition of goat anti-human plasminogen (1:1,000) or goat anti-human FH (1:1,000),
HRP-conjugated rabbit anti-goat (1:20,000), and 2,2’-azino-bis(3-ethylbenzothiazoline6-sulphonic acid). Plasminogen binding is represented as % binding relative to the 5:1
molar ratio, and FH binding is represented as % binding relative to the 0:1 molar ratio.
Error bars indicate standard deviations.
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Type 1

Type 2

Type 3

Figure 3-5. FhbB phyletic type does not alter plasminogen binding. Recombinant
FhbB proteins isolated from each phyletic type were immobilized in an ELISA plate,
coated with plasminogen, and binding detected as previously described. The isolate of
origin and phyletic type designation are indicated on the x-axis. Binding is represented
as % binding relative to the wild type r-35405 FhbB. Results are representative of 3
independent experiments; error bars indicate standard deviations. **P < 0.001
compared to 35405 (Student t test).
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presence of FH cleaved C3b as demonstrated by the appearance of the C3dg cleavage
product (Figure 3-6, lane 5). The presence of intact C3b α’ and β-chains confirmed that
plasminogen itself cannot serve as a cofactor in the FI-mediated degradation of C3b
(Figure 3-6, lane 3). In the presence of plasminogen, FH, and FI, C3b cleavage was not
enhanced as seen by C3dg cleavage products at roughly the same intensity as
conditions where plasminogen is absent (Figure 3-6, lanes 5, 7-9).

Therefore,

plasminogen binding to FhbB does not enhance Factor I-mediated cleavage of C3b. It
is also of note that increasing concentrations of plasminogen did not diminish C3b
degradation, providing further evidence that FH and plasminogen do not compete for
binding to FhbB.

The T. denticola protease dentilisin degrades plasminogen.
T. denticola is highly proteolytic and the most characterized of its proteases is
dentilisin. Dentilisin is important in T. denticola periodontal pathogenicity as it has been
shown to have a variety of functions including cleavage of key complement proteins C3,
C3b, and FH (20, 22, 57, 108). To assess dentilisin activity of T. denticola strains used
in this study, SAAPFNA assays were conducted (Figure 3-7A). The dentilisin positive
strain, 35405, and dentilisin deficient mutant strain, CCE, served as positive and
negative controls, respectively.

Dentilisin activity at or below the level of CCE is

considered background and the strain is designated as dentilisin deficient (33521,
SP54, and SP72). Dentilisin activity 3 logs above CCE is considered above background
and the strain is designated as dentilisin positive (SP61 and SP46).
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Figure 3-6. Plasminogen does not enhance cofactor-assisted cleavage of C3b by
Factor I. Combinations of plasminogen (1, 5, or 10 µg), Factor H, and Factor I were
added to C3b and T. denticola CCE (dentilisin mutant) cells. The reaction mixture was
assessed by SDS-PAGE and C3b degradation products were visualized by Western
blotting using goat anti-human C3 (1:1000) and HRP-conjugated goat antiserum.
Additional control reactions with CCE cells incubated with various combinations of
purified human plasminogen, C3b, FI, and/or FH were performed and analyzed as
described above.
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A.

B.

Figure 3-7. T denticola cleavage of plasminogen is dentilisin dependent.

A,

dentilisin activity of T. denticola strains was quantitated by SAAPFNA hydrolysis
measured at 405 nm, as described in methods. Dentilisin activity is represented as %
hydrolysis relative to 35405; (‘) denotes minutes.

Results are representative of 3

independent experiments; error bars indicate standard deviations.

B, dentilisin

cleavage of plasminogen was assessed by incubating T. denticola cells with
plasminogen for 2 hours. Plasminogen degradation was detected by screening with
human plasminogen antiserum.
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Dentilisin has been demonstrated to cleave T. denticola surface-bound FH (60).
As plasminogen and FH have been shown to bind FhbB simultaneously (Figure 3-4),
the ability of dentilisin to degrade plasminogen was evaluated. Dentilisin positive or
negative T. denticola strains were incubated with plasminogen for 2 hours and
separated by SDS-PAGE.
plasminogen antiserum.

Plasminogen degradation was detected using human

Complete degradation of plasminogen was observed at 2

hours in dentilisin positive strains while dentilisin negative strains were unable to cleave
plasminogen (Figure 3-7B). Therefore, in addition to cleavage of C3, C3b, and FH,
dentilisin is also able to degrade the zymogen, plasminogen.

T. denticola surface-bound plasminogen is activated to plasmin.
Plasminogen is activated to the serine protease plasmin by human activators
such as urokinase (uPA) (7).

In order for these activators to proteolytically cleave

plasminogen, the appropriate domain of plasminogen must be accessible. Through the
use of the chromogenic substrate

D-Val-Leu-Lys

4-nitroanilide dihydrochloride, we

demonstrated that T. denticola-bound plasminogen is accessible to human uPA and is
cleaved to proteolytically active plasmin (Figure 3-8).

Plasmin activity of all six T.

denticola strains incubated with urokinase and plasminogen was significantly higher
than plasminogen activation for the control reactions.
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A.

B.
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Figure 3-8. Analysis of plasminogen activation on the T. denticola cell surface. T.
denticola strains 35405, SP61, and SP46 (A) and CCE (dentilisin gene inactivation
mutant), 33521 (natural dentilisin deficient strain), and SP54 (B) were incubated alone
(purple), with the activator urokinase (uPA) (green), with plasminogen (red), or with
plasminogen and uPA (blue). After washing, the chromogenic substrate D-Val-Leu-Lys
4-nitroanilide dihydrochloride was added, and conversion of the substrate was
determined by measuring absorbance at 405 nm (A405). Plasmin activity at 8 hours for
all strains incubated with plasminogen and urokinase was significantly higher compared
to control reactions (P < 0.0001, Student t test).
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Chapter 4: Discussion

Due to its location in the periodontal plaque biofilm, Treponema denticola is in
direct contact with the gingival crevicular fluid produced by the gingival epithelium.
Evasion of complement mediated destruction is essential for the periopathogen’s
survival as GCF recovered from diseased patients is rich in immune effectors including
complement (12). The primary mechanism of T. denticola serum resistance is binding
of FH to the protein FhbB (57). The binding interaction enables T. denticola to regulate
the alternative complement pathway at the level of C3b through a variety of
mechanisms (84, 85, 105). Numerous pathogenic bacteria have been shown to utilize
the negative regulatory function of FH by binding FH to proteins present on the cell
surface (23, 109).

In addition to FH, many of these surface proteins also bind

plasminogen (23).
Plasminogen is a host-derived glycoprotein that circulates in plasma as an
inactive zymogen. It is converted to its active serine protease form, plasmin, through
cleavage by plasminogen activators such as staphylokinase and urokinase.

Most

pathogenic bacteria utilize the serine protease function of plasmin, and interact with the
plasminogen system by secreting plasminogen activators or expressing plasminogen
receptors on their surface (77). Activated plasmin is able to degrade ECM components
and regulate the immune response through cleavage of complement proteins and
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immunoglobulin molecules. These functions facilitate the invasion and dissemination of
pathogenic microbes (48, 49).
In the present study, we show that FhbB is a novel plasminogen-binding protein.
The kringle domains, located within the native form of plasminogen, mediate proteinprotein interactions through binding of lysine residues to the kringles’ LBS. The lysine
analogue, ε-ACA, was able to compete out plasminogen binding to FhbB demonstrating
that FhbB lysine residues interact with the kringle LBS during the binding interaction.
Recently, the FhbB FH binding site was characterized to residues located on the
negatively charged surface while the positively charged surface appeared unoccupied.
Mutations to negatively charged residues E45, D58, and E62 completely abolished FH
binding to FhbB (66).

Using site directed mutagenesis, this study indicates that

positively charged residues K47, H50, K77, K78, R93, and K94 are important for the
interaction of FhbB with plasminogen while mutations to negatively charged residues
have little to no effect.

Although plasminogen typically mediates binding via lysine

residues, other plasminogen binding proteins, such as the group A streptococcal M-like
protein (PAM), mediate the interaction through arginine and histidine residues even in
the presence of lysine residues (86). Unlike FH binding, alanine substitution of any one
of the positively charged residues does not completely eliminate plasminogen binding.
This may be due to the localization of the negatively charged electrostatic environment
compared to the positively charged electrostatic environment which is less localized on
the protein (Figure 3-3A). Also, the negatively charged mutations represent all possible
negative amino acids whereas we only mutated 4 of the 10 positive residues on the
positively charged surface. The ε-ACA and site directed mutagenesis results suggests
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that plasminogen binding is a multi-contact point interaction mediated by positively
charged lysine, arginine, and histidine residues present on the positively charged face
of FhbB. If true, we would expect that FH and plasminogen do not compete for binding
as they bind to negatively and positively charged residues, respectively.

Our

competition analyses confirm that FH and plasminogen do not compete for binding.
Together, these data demonstrate that FhbB uses positively and negatively charged
residues on opposite faces to bind plasminogen and FH, respectively.
In order to establish infection, T. denticola must evade the destructive effects of
complement. The serum resistance of T. denticola is dependent on the binding of FH to
FhbB (57). Earlier studies with FhbB suggested that it is highly conserved among T.
denticola isolates, but recently a divergent FhbB protein was identified in strain 33521
(58, 67). The Marconi lab sequenced fhbB from over 30 different isolates and revealed
three major phyletic types (type 1, 2, and 3) (Marconi RT unpublished data, Figure 1-3).
There is ~70% similarity and ~60% identity between types, and sequence variations are
localized to the negatively charged FH binding site of FhbB. The positively charged
surface is more conserved across types with ~88% similarity and ~70% identity. Also,
all lysine and arginine residues present on the positively charged surface are conserved
across the three phyletic types (Figure 4-1). To determine if sequence variation across
FhbB phyletic types affect plasminogen binding, an ELISA assay was used. The results
demonstrate that there are no major differences in plasminogen binding to the three
FhbB phyletic types. This is consistent with the high sequence conservation of the
positively charged face of FhbB which appears to serve as the plasminogen binding
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Figure 4-1.

Sequence alignment of mature FhbB from various T. denticola

isolates. Alignment was generated by MEGA5. Identical amino acids are indicated by
(.) and gaps are indicated by (-). The signal peptide sequence is underlined, and the
residues present on the negatively and positively charged surface of FhbB are depicted
in red and blue, respectively. High conservation of the lysine and arginine residues on
the positively charged surface are shown in bold.
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interface. This further demonstrates that FhbB uses separate contact sites on opposite
faces for plasminogen and FH.
Plasminogen has been shown to enhance cofactor-mediated inactivation of C3b
by the complement protease Factor I (3).

To assess the overall contribution of

plasminogen to C3b cleavage, CCE cells (dentilisin deficient) and C3b were incubated
with increasing concentrations of plasminogen in the presence of FH and FI.
Plasminogen binding to FhbB does not enhance cleavage of C3b in the presence of FH
and FI. The assay also demonstrates that plasminogen itself cannot degrade C3b, and
that it does not act as a cofactor for FI-mediated degradation of C3b.

Although

plasminogen itself cannot cleave C3b, the activated protease form, plasmin, has been
shown to cleave C3b (3). Future analyses will determine whether activation of FhbBbound plasminogen to plasmin enhances C3b degradation or the cofactor activity of FH.
It is important to note that plasminogen binding did not decrease the cofactor activity of
FH providing further evidence that plasminogen and FH bind to separable sites and do
not compete.
T. denticola produces numerous proteases that mediate processes that are
important in T. denticola pathogenesis (2, 4, 19, 21, 30, 51-53, 65, 70, 82, 96).
Dentilisin is the best characterized of this group, and has been shown to cleave several
host proteins including surface bound FH (2, 9, 18, 60, 68, 108). The dentilisin activity
of the T. denticola strains used in this study was determined by a SAAPFNA assay;
strains 35405, SP46, and SP61 are dentilisin positive while strains CCE, 33521, SP54,
and SP72 are dentilisin deficient. In the presence of dentilisin positive strains 35405,
SP46, and SP61, plasminogen was successfully degraded at 2 hours demonstrating
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that dentilisin cleaves plasminogen.

In the presence or absence of dentilisin,

plasminogen bound to T. denticola is accessible to the activator uPA and is converted to
active protease plasmin.
Given the many functions of plasmin(ogen) discussed in the introduction, FhbB
binding of plasminogen in addition to FH could provide the periopathogen with
additional mechanisms to evade both the innate and adaptive immune response.
Plasminogen can bind to the complement proteins, C3 and C5, and activated plasmin
can cleave C3b and generate unique C3b fragments (3). A paradox in FhbB FH binding
is the cleavage of surface-bound FH by the protease dentilisin (60). If dentilisin cleaves
FH to depletion, T. denticola would presumably be more susceptible to complement
mediated destruction.

By binding plasminogen to the surface and activating it to

plasmin, T. denticola could degrade the opsonin C3b deposited on its surface, and
plasmin could bind to and degrade C5 thereby preventing cell lysis by blocking the
formation of the MAC. Plasmin can also degrade immunoglobulin molecules (11, 33,
41, 101). Thus, in addition to C3b and C5 cleavage, activated plasmin on the surface of
T. denticola could cleave the Ig opsonins, further reducing opsonization while
simultaneously blocking activation of the classical complement pathway. T. denticola in
concert with Prophyromonas gingivalis can keep plasmin activated as both
periopathogens are able to degrade the host plasmin inhibitor, antiplasmin (29). This
would provide evasion mechanisms independent of FH binding that allow the
periopathogen to evade both innate and adaptive immunity to continue to establish
infection.
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Another role of plasmin is its activation of matrix metalloproteinases (MMPs) (45).
MMPs are a group of enzymes responsible for the degradation of various kinds of
extracellular matrix proteins including collagen (92). The collagenases are secreted in a
proenzyme form and require proteolytic cleavage for activation. Plasmin can activate
procollagenases and thus act in concert with other proteinase systems (such as
dentilisin) in ECM breakdown (55, 69, 104). Recent studies have demonstrated that the
presence of T. denticola in the periodontal pocket is associated with increased levels of
MMP-9 in gingival crevicular fluid (90, 107). MMP-9 has the ability to break down type I
and type III collagen which is critical for periodontal destruction as gingival fibers are
primarily composed of type I and type III collagen (5, 8).

Gingival fibers are the

connective tissue fibers that inhabit the gingival epithelium adjacent to teeth and help
hold the tissue firmly against the teeth (38). Gingival fibers cannot be regenerated and
when the fibers are destroyed, the periodontal pocket depth increases, allowing bacteria
to invade deeper into periodontal tissue.

There is evidence that plasmin(ogen) is

directly involved in the activation of MMP-9 (26, 28, 47). This suggests that T. denticola
may bind plasminogen to its surface and activate it to plasmin which can then
subsequently activate the high levels of GCF MMP-9 associated with periodontal
disease. Activated MMP-9 could break down the gingival fibers creating a deeper, more
anaerobic periodontal pocket where T. denticola can thrive.
In summary, my research demonstrates that FhbB is a multifunctional protein
that binds plasminogen and FH. After binding, plasminogen is cleaved into its protease
form, plasmin. The binding and activation of plasminogen is extremely important for
understanding periodontal disease progression and severity. Activated plasmin could
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evade the host immune response encountered in the gingival crevicular fluid via
cleavage of complement components and Ig molecules. Evasion of innate and adaptive
immunity may enable T. denticola to enter the bloodstream and disseminate to
secondary sites of infection such as the heart (reviewed in 76). The activated plasmin
could also activate MMP9 to break down components of the periodontal tissue allowing
for deeper invasion.

The ensuing tissue destruction would benefit T. denticola by

increasing nutrient availability and by creating a larger anaerobic environment where the
bacteria can flourish, thereby promoting periodontal disease.
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